Antiserum to lymphocytes and procarbazine compared as immunosuppressants in mice

Science
P B Stewart, V Cohen

Abstract

As an immunosuppressant procarbazine was as potent as an antiserum to lymphocytes in mice. Both agents significantly prolonged survivals of skin allografts by 4 to 6 weeks. At the maximum tolerated dosage, procarbazine suppressed both circulating hemagglutinins to sheep erythrocytes and plaque-forming cells in the spleen. The antiserum to lymphocytes reduced the numbers of circulating hemagglutinins and plaque-forming cells by 94 percent. Procarbazine was administered to mice for 3 weeks before their exposure to antigen. Exposure for only 9 days, commencing 48 hours before injection of sheep erythrocytes, was less effective in suppressing the titers of hemagglutinins.

Citations

Jun 1, 1981·Immunopharmacology·M A Baig, A A Ansari
Jan 1, 1980·Pharmacology & Therapeutics·W M Shannon, F M Schabel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.